BRUCELLA SUIS (SWINE BRUCELLOSIS)
LEVELS: Likely to occur: Effective control measures not fully understood; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations; No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Brucella suis is a gram-negative intracellular coccobacillus that causes swine brucellosis, a disease of major zoonotic importance. It is the predominant cause of brucellosis in swine, though B. abortus and B. melitensis can also infect pigs in regions where they are endemic in cattle and small ruminants. B. suis is divided into five biovars, with biovars 1, 2, and 3 infecting swine. Biovars 1 and 3 are highly pathogenic to humans, while biovar 2 (predominant in European wild boar) causes human disease only rarely in immunocompromised individuals. In swine, brucellosis causes reproductive losses including abortion, stillbirths, infertility in females, and orchitis/epididymitis in males. Clinical signs are often mild or absent in chronically infected herds, making detection difficult. The organism can persist for years in reproductive tissues with intermittent shedding. Transmission occurs primarily through ingestion of infected reproductive tissues, venereal contact (unique among Brucella species), and transplacental infection. Feral swine and wild boar serve as significant wildlife reservoirs in many regions, complicating control efforts. Human brucellosis ("undulant fever") is the world's most common bacterial zoonosis with over 500,000 new cases annually; B. suis is among the most virulent human pathogens in the genus. Control in domestic swine relies on biosecurity, test-and-slaughter programs, and preventing contact with infected wildlife. No effective swine vaccine is commercially available.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Likely to occur: Effective control measures not fully understood
Foodborne transmission to humans is documented: (1) Direct pork consumption: "Some data suggests that zoonotic infection with B. suis can result from handling or consumption of infected raw or undercooked pork"; (2) Dairy transmission: "Published reports have documented zoonotic transmission of B. suis to groups of people through consumption of unpasteurized bovine milk"—this occurs when B. suis spills over from pigs to cattle and localizes in mammary tissue; (3) Global burden: "Brucellosis is the world's most common bacterial zoonosis, with over half a million new cases annually"; (4) Virulence: "Brucella melitensis and B. suis are generally more virulent human pathogens than other Brucella spp."
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
Occupational and direct contact transmission is well-documented and represents the primary zoonotic route: (1) High-risk occupations: "Human brucellosis due to B. suis most frequently occurs in farm workers, veterinarians, and abattoir employees"; (2) Abattoir risk: "Processing of infected swine through an abattoir is associated with a high risk for infection of human workers, most likely through aerosol exposure"; (3) Hunting exposure: "it can also be contracted through hunting or association with feral swine"; recent reports document cases in feral swine hunters; (4) Multiple routes: "Routes of entry include aerosol, oral, or through breaks in epidermal integrity"; (5) Historical impact: "Prior to the initiation of the eradication program in the United States in 1959, the number of reported human cases in the United States peaked at 6321 in 1949 with most cases attributed to infections with B. abortus and B. suis"; (6) Laboratory hazard: "manipulation of cultures or contaminated material from potentially infected animals should be done under Biosafety Level 3 (BSL3) laboratory conditions."
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
Multiple routes allow B. suis to bypass standard biosecurity: (1) Wildlife reservoirs: "feral swine or wild boar are the predominant reservoir host for B. suis in many countries"; European wild boar prevalence "ranging from 42 to 55% throughout continental Europe"; US feral swine serve as ongoing reservoir; (2) Venereal transmission: "Unlike most other brucellae, B. suis can be spread by venereal transmission, which appears to be important for transmission within and between herds"; infected semen through AI is a risk; (3) Latent carriers: "Neonatal infection may lead to a latent carrier state that could result in disease transmission in the absence of clinical and immunological signs"; (4) Prolonged shedding: Males can remain infected "up to 3–4 years"; females shed for "up to 36 months"; (5) Outdoor production: "porcine brucellosis in domestic swine is almost exclusively in swine raised outdoors and related to spillover of B. suis biovar 2 from wild boars"; (6) Environmental survival: "Brucella can survive in a cold moist environment for up to several months and in infected aborted fetuses or fluids." However, "environmental persistence of B. suis is considered of low epidemiological importance" compared to direct transmission.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Diagnosis is complicated by chronicity and test limitations: (1) Culture is definitive but challenging: "Bacterial culture is the definitive method for confirming brucellosis in swine" but has "slow growth of Brucella in vitro, a tendency for reduced isolation from chronically infected swine, high costs, and biosafety concerns"; (2) Serologic limitations: "The diagnostic value of serological tests for brucellosis in swine is only useful at the herd level rather than for individual swine"; "None of the conventional serological tests...have adequate sensitivity and specificity for the diagnosis of B. suis infections in individual pigs"; (3) False negatives: "a panel of serologic tests only identified 52% of naturally infected feral swine as seropositive"; "17% of culture-positive swine were negative on all serologic tests"; (4) Cross-reactions: Yersinia enterocolitica O:9 and E. coli O:157 cause false positives; (5) Subclinical infection: "only mild to moderate clinical signs are observed" in chronically infected herds; (6) PCR available: Multiple PCR protocols reported but "sensitivity...is currently significantly lower than culture methods for some samples"; (7) DTH test: Brucellin delayed-type hypersensitivity test is "the only indirect diagnostic test capable of discriminating between B. suis infections and infections caused by cross-reacting bacteria."
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
B. suis causes substantial reproductive and production losses: (1) Reproductive failure: "abortion, stillbirths, and infertility in sows, orchitis, epididymitis, and infertility in boars"; (2) Rapid herd spread: "When first entering a naive herd, B. suis can quickly spread from a single infected animal resulting in infection rates of up to 70–80%"; (3) Multiple pregnancy effects: Infection near conception causes "fetal death by 21–27 days" recognized as irregular returns; later infection causes "abortion of fetuses of various sizes, stillborn pigs, or infected live-born pigs that exhibit increased neonatal mortality rates"; (4) Chronic infertility: "Infertility is directly related to the duration of infection and the severity of uterine lesions"; persistent uterine infection causes "temporary or permanent infertility"; (5) Boar effects: "libido and fertility can be decreased...resulting in reduced conception rates and litter sizes"; (6) Regulatory costs: Test-and-slaughter programs, movement restrictions, and biosecurity investments add significant costs; (7) Endemic impact: China experiences "high levels of swine production, sporadic reports of epidemics of B. suis in swine."
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms
B. suis triggers major regulatory and trade consequences: (1) Regulatory programs: "Human brucellosis is the primary basis for control or eradication programs targeting Brucella spp. in domestic livestock hosts"; (2) US eradication program: Initiated 1959; successfully reduced human cases from 6321 (1949) to average 159/year since 1973; (3) International status: Many countries have official brucellosis-free status for domestic swine; positive herds face severe restrictions; (4) Herd depopulation: Test-and-slaughter is standard regulatory approach; (5) Movement restrictions: Infected herds face quarantine; "the risk of disease transmission from wildlife reservoirs to domestic swine is unlikely to diminish with currently available intervention strategies"; (6) Seedstock impact: Introduction through infected semen or breeding stock is a major risk requiring testing and quarantine; (7) Zoonotic concerns drive policy: Programs "justified by data, which indicates that addressing the disease in livestock reservoirs is the most efficient and economical approach for reducing human brucellosis."
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Antimicrobial resistance is not a significant concern for B. suis: (1) No natural plasmids: "Brucella spp. have no known natural plasmids with which to transfer genetic material or antibiotic resistance"; (2) Treatment not standard: Antimicrobial treatment of infected swine is not a recommended control strategy due to failure to clear infection; (3) Human treatment concerns: In human medicine, prolonged antibiotic courses are used, but resistance emergence in Brucella remains uncommon; (4) Intrinsic characteristics: The intracellular lifestyle of Brucella limits antimicrobial efficacy rather than acquired resistance being the issue.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Swine brucellosis management does not drive antimicrobial use: (1) Treatment not recommended: "test and removal strategies" rather than antibiotic treatment are standard; (2) Treatment ineffective: Studies found antibiotic therapy "although disease prevalence was reduced, cost of treatment and persistence of infection in some treated animals made long-term antibiotic therapy nonviable as a regulatory strategy"; (3) Limited efficacy: "oral treatment with oxytetracycline...eliminated B. suis biovar 2 infection from only 50% of infected swine"; even combined therapy couldn't reliably clear infection; (4) Regulatory approach: "regulatory efforts to control or eradicate B. suis in domestic swine should be directed toward herds, rather than individual animals" through test-and-slaughter, not treatment.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations
Treatment is not a viable control strategy for swine brucellosis: (1) Regulatory approach predominates: Test-and-slaughter rather than treatment is standard for regulatory control; (2) Treatment failure: Antibiotic studies showed incomplete clearance; "cost of treatment and persistence of infection in some treated animals made long-term antibiotic therapy nonviable"; (3) Intracellular survival: Brucella's ability to survive within host cells limits antimicrobial efficacy; (4) Chronic infection: Organisms persist in reproductive tissues for years despite host immune responses; (5) Field study failure: "oral treatment of naturally infected swine...with oxytetracycline was not sufficient to eradicate brucellosis in infected herds." Treatment may have limited value for individual high-value animals but is not practical for herd control.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No commercial swine vaccine exists: (1) No products available: "There are currently no commercially available vaccines for protecting domestic or feral swine against B. suis infection"; (2) Failed candidates: "currently available data suggests that the oral B. suis strain 2 vaccine developed in China and the B. abortus strain RB51 vaccine do not adequately protect swine against B. suis infection"; (3) Research vaccines: "a rough B. suis strain that can be used as a differentiating infected from vaccinated animals (DIVA) vaccine was demonstrated to have efficacy" but is not commercially available; (4) Development challenges: "At the current time, commercial development of a B. suis vaccine in the United States does not appear to be imminent"; (5) Wildlife application research: "Current research in swine evaluating immunocontraception, toxin-containing baits, and orally deliverable vaccines may eventually provide needed tools" for feral swine management.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
National eradication is not achievable due to wildlife reservoirs: (1) Feral swine reservoir: "feral swine or wild boar are the predominant reservoir host for B. suis in many countries"; "In the United States, the highest disease prevalence is in feral pigs in south central and southeastern states"; (2) No wildlife control tools: "Except for increasing hunting pressure to reduce population densities, measures are not available to reduce or eliminate B. suis infections in wildlife reservoirs"; (3) Ongoing transmission risk: "the risk of disease transmission from wildlife reservoirs to domestic swine is unlikely to diminish with currently available intervention strategies"; (4) Outdoor production vulnerable: Swine raised outdoors remain at risk from wildlife contact; (5) Domestic swine success: The US eradication program successfully eliminated B. suis from commercial domestic swine operations through test-and-slaughter and biosecurity; (6) Reintroduction risk: Proximity to infected feral populations creates ongoing reintroduction risk; "elimination of brucellosis from a farm may only be transient if neighboring farms remain infected." True national eradication would require eliminating the feral swine reservoir, which is not currently feasible.